Women with high-risk congenital heart disease can safely become pregnant and give birth if they are carefully monitored and managed by doctors, according to a new scientific statement by the American Heart Association. “Management Of Pregnancy In Patients With Complex Congenital Heart Disease: A Scientific Statement For Healthcare Professionals…
Almost one-fourth of pulmonary arterial hypertension (PAH) patients in a small recent study had pulmonary artery aneurysm (PAA), a condition marked by serious heart complications. Its researchers recommend that PAH patients with signs of heart failure be screened for aneurysms. The study, “Cardiac Dysfunction Of Pulmonary Artery Aneurysm In…
A recent study showed that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) responded well to a combination therapy with ambrisentan and tadalafil, with a lower incidence of clinical failure when compared to therapy with either drug alone. The response, however, was not as impressive when compared to initial use of the…
SteadyMed Therapeutics recently reported its strategic goals and priorities for 2017, including plans to file a New Drug Application (NDA) to market Trevyent in the U.S., the company’s lead candidate to treat pulmonary arterial hypertension (PAH). Trevyent is based on treprostinil, the only parenteral therapy for PAH approved by the…
Vivus has acquired the global exclusive rights from Selten Pharma to develop and commercialize tacrolimus and ascomycin, two investigational treatments for pulmonary arterial hypertension (PAH) and other vascular diseases. Vivus, a biopharmaceutical company based on Campbell, California, acquired Selten’s licence to a series of patents owned by the Board of…
Researchers have identified a disease mechanism that could be targeted to develop treatments for pulmonary arterial hypertension (PAH). In a rat model of PAH, a compound that reduces oxidative stress lowered pulmonary pressure and prevented remodeling of lung blood vessels. Oxidative stress is a major contributor to the events leading…
The U.S. Food and Drug Administration (FDA) accepted several modifications proposed by Bellerophon Therapeutics for its Phase 3 program to evaluate the efficacy and safety of INOpulse in patients with pulmonary arterial hypertension (PAH). Under the new testing program, INOpulse may be ready for FDA review and possible…
Eiger BioPharmaceuticals recently announced that a first patient has completed the 24-week dosing in the Phase 2 LIBERTY study assessing ubenimex as a therapy for pulmonary arterial hypertension (PAH). That patient is now continuing with treatment in an open-label extension trial. “There has been tremendous enthusiasm in the entire community — patients, families,…
A triple combination therapy with Tracleer (bosentan), Viagra (sildenafil), and Veletri (epoprostenol) can completely reverse right ventricular remodeling that occurs in pulmonary hypertension, according to a case study published in the medical journal Respiratory Medicine Case Reports.
Noninvasive methods can help to determine which patients have a high probability of developing pulmonary hypertension (PH) and which are most unlikely to do so, researchers reported — offering clinicians further tools when examining people with suspected lung hypertension. The study, “Use of ECG and Other Simple Non-Invasive Tools…
Statins added to pulmonary hypertension (PH) treatment do not provide any clinical benefit for a clear majority of patients — although this drug’s use in those whose PH is the result of chronic obstructive pulmonary disease (COPD) show some “intriguing” points worthy of further study, researchers…
A woman with the genetic disease neurofibromatosis type 1 (NF1) who developed pulmonary hypertension (PH) was successfully treated with a combination of increased pulmonary arterial hypertension (PAH)-specific therapy and surgery that created a hole between her two heart chambers. The study, “Atrial septostomy and disease targeting…
Get regular updates to your inbox.